Biora Therapeutics Inc (BIOR) Stock Price, Quote & News

Company Profile

Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases. The company was formerly know...

Industry: Biotechnology

Sector: Healthcare

Phone: 833 727 2841

Website: www.bioratherapeutics.com

Address:

4330 La Jolla Village Drive, Suite 300, San Diego, United States

Coversoon Jun. 3 at 2:41 PM

$BIOR Criminals

0 · Reply

Herkules369 May. 30 at 3:24 PM

$BIOR Jackpo 🎰

0 · Reply

Coversoon May. 27 at 10:10 PM

$BIOR 25k watchers!!! On this pos. Sure!!! Criminal run enterprise led by a freaking liar. All should be have been prosecuted by doj including the board of directors

1 · Reply

Coversoon May. 27 at 10:06 PM

$BIOR C R I M I N A L S

0 · Reply

Rainbowz20 May. 25 at 8:04 PM

$BIOR does anyone know what happens to our shares when a company goes private. I had some shared in this POS for a long time I forgot about. Am UK based. Thanks

1 · Reply

Ajmh May. 20 at 11:28 AM

$BIOR AstraZeneca is one of the confirmed collaborators; the others are anonymous. Current Status After successfully completing the legal restructuring process, the company's CEO, Adi Mohanty, confirmed that Biora Therapeutics has emerged from bankruptcy and become a private company with a healthy balance sheet. The company is currently maintaining its operations with a sole focus on the technical and commercial advancement of its BioJet™ oral autoinjection platform.

4 · Reply

Ajmh May. 20 at 11:25 AM

$BIOR Yes, after completing its bankruptcy restructuring process, Biora Therapeutics ceased to be a publicly traded company and became a private company. Ownership of its patents, technologies, and operating assets was transferred to a new corporate entity registered as BT Bidco Inc. (which operates under the trade name Biora Therapeutics). The company's current owners are a group of its former secured creditors, who assumed full control after executing a credit offer and exchanging the company's debt for control of its assets in bankruptcy court. The majority investment funds that control the company are: Highbridge Capital Management LLC: A US hedge fund focused primarily on healthcare investments and equity arbitrage. Davidson Kempner Capital Management LP: A global institutional investment management firm. Context Capital Management LLC: A firm specializing in fixed income strategies and arbitrage.

0 · Reply

jeni1988 May. 19 at 1:54 PM

$BIOR Alive?

0 · Reply

Ajmh May. 14 at 7:17 PM

$BIOR 🤦🏽🤦🏽🤦🏽🤦🏽🤦🏽🤦🏽🤦🏽🤦🏽🤦🏽 https://www.biospace.com/press-releases/biora-therapeutics-advances-biojet-swallowable-autoinjector

2 · Reply

Coversoon May. 8 at 4:07 PM

$BIOR C R I M I N A L S !!!!!!!

0 · Reply

Biora Therapeutics Quarterly report: Q3 2024

Nov 14, 2024, 4:00 PM EST - 1 year ago

Biora Therapeutics Earnings release: Q3 2024

Nov 14, 2024, 8:00 AM EST - 1 year ago

Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Nov 7, 2024, 4:30 PM EST - 1 year ago

Biora Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update

Oct 29, 2024, 8:00 AM EDT - 1 year ago

Biora Therapeutics Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Oct 28, 2024, 8:00 AM EDT - 1 year ago

Biora Therapeutics Shares Progress on Smaller BioJet™ Clinical Device with Largest Payload of any Ingestible Injectable at the 14th Annual PODD Meeting

Oct 23, 2024, 8:00 AM EDT - 1 year ago

Biora Therapeutics Proxy statement: Proxy Filing

Oct 11, 2024, 8:00 AM EDT - 1 year ago

Biora Therapeutics Proxy statement: Proxy Filing

Sep 16, 2024, 8:00 AM EDT - 1 year ago

Biora Therapeutics Proxy statement: Proxy Filing

Sep 11, 2024, 1:30 PM EDT - 1 year ago

Biora Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 8:00 AM EDT - 1 year ago

Biora Therapeutics Proxy statement: Proxy Filing

Aug 26, 2024, 8:00 AM EDT - 1 year ago

Biora Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

Aug 23, 2024, 8:00 AM EDT - 1 year ago

Biora Therapeutics Registration statement: Registration Filing

Aug 13, 2024, 2:30 PM EDT - 1 year ago

Biora Therapeutics Transcript: Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024

Aug 12, 2024, 4:30 PM EDT - 1 year ago

Biora Therapeutics Earnings Call Transcript: Q2 2024

Aug 12, 2024, 4:30 PM EDT - 1 year ago

Biora Therapeutics Quarterly report: Q2 2024

Aug 12, 2024, 4:30 PM EDT - 1 year ago

Biora Therapeutics Earnings release: Q2 2024

Aug 12, 2024, 4:15 PM EDT - 1 year ago

Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

Aug 12, 2024, 4:05 PM EDT - 1 year ago

Biora Therapeutics Announces Funding Agreement with Existing Investors

Aug 8, 2024, 4:30 PM EDT - 1 year ago

Biora Therapeutics to Report Second Quarter 2024 Financial Results and Provide Corporate Update

Jul 17, 2024, 2:00 PM EDT - 2 years ago

Biora Therapeutics Transcript: Study Update

Jul 17, 2024, 2:00 PM EDT - 2 years ago

Biora Therapeutics Press release: Study Update

Jul 17, 2024, 2:00 PM EDT - 2 years ago

Biora Therapeutics Slides: Study Update

Jun 11, 2024, 8:00 AM EDT - 2 years ago

Biora Therapeutics Announces Presentation on the BioJet™ Systemic Oral Delivery Platform at the Next Gen Peptide Formulation & Delivery Summit 2024

May 20, 2024, 8:00 AM EDT - 2 years ago

Biora Therapeutics Presents Clinical Data on Device Function of the NaviCap™ Platform at Digestive Disease Week 2024

May 20, 2024, 8:00 AM EDT - 2 years ago

Biora Therapeutics Registration statement: Registration Filing

May 20, 2024, 8:00 AM EDT - 2 years ago

Biora Therapeutics Registration statement: Registration Filing

May 15, 2024, 4:30 PM EDT - 2 years ago

Biora Therapeutics Earnings Call Transcript: Q1 2024

May 15, 2024, 4:30 PM EDT - 2 years ago

Biora Therapeutics Quarterly report: Q1 2024

May 15, 2024, 4:30 PM EDT - 2 years ago

Biora Therapeutics Earnings release: Q1 2024

May 15, 2024, 4:05 PM EDT - 2 years ago

Biora Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

May 7, 2024, 8:00 AM EDT - 2 years ago

Biora Therapeutics to Report First Quarter 2024 Financial Results and Provide Corporate Update

May 6, 2024, 8:00 AM EDT - 2 years ago

Biora Therapeutics to Present Clinical Data on Device Function of the NaviCap™ Oral Delivery Platform at Digestive Disease Week 2024

Apr 30, 2024, 8:00 AM EDT - 2 years ago

Biora Therapeutics Announces Completion of Multiple-Ascending Dose (MAD) Cohorts for Clinical Trial of BT-600

Apr 24, 2024, 8:00 AM EDT - 2 years ago

Biora Therapeutics Proxy statement: Proxy Filing

Apr 24, 2024, 8:00 AM EDT - 2 years ago

Biora Therapeutics Proxy statement: Proxy Filing

Apr 12, 2024, 8:00 AM EDT - 2 years ago

Biora Therapeutics Proxy statement: Proxy Filing

Apr 8, 2024, 8:00 AM EDT - 2 years ago

Biora Therapeutics Announces New Patent Covering its BioJet™ Liquid Jet Delivery Technology

Apr 8, 2024, 8:00 AM EDT - 2 years ago

Biora Therapeutics Registration statement: Registration Filing

Apr 4, 2024, 8:00 AM EDT - 2 years ago

Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development

Apr 3, 2024, 4:05 PM EDT - 2 years ago

Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Apr 1, 2024, 8:00 AM EDT - 2 years ago

Biora Therapeutics Announces $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Mar 26, 2024, 4:30 PM EDT - 2 years ago

Biora Therapeutics Earnings Call Transcript: Q4 2023

Mar 26, 2024, 4:30 PM EDT - 2 years ago

Biora Therapeutics Annual report: Q4 2023

Mar 26, 2024, 4:30 PM EDT - 2 years ago

Biora Therapeutics Earnings release: Q4 2023

Mar 26, 2024, 4:05 PM EDT - 2 years ago

Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results

Mar 18, 2024, 8:00 AM EDT - 2 years ago

Biora Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update

Mar 11, 2024, 8:00 AM EDT - 2 years ago

Biora Therapeutics Further Reduces Net Debt and Monetizes Legacy Asset

Feb 26, 2024, 8:00 AM EST - 2 years ago

Biora Therapeutics Announces Successful Completion of Single-Ascending Dose (SAD) Cohorts of Phase 1 Clinical Study of BT-600

Feb 8, 2024, 8:00 AM EST - 2 years ago

Biora Therapeutics Announces Participation in Canaccord Genuity Inflammatory Bowel Disease Symposium

Jan 29, 2024, 11:00 AM EST - 2 years ago

Biora Therapeutics Transcript: Fireside Chat

Jan 22, 2024, 8:00 AM EST - 2 years ago

Biora Therapeutics Announces Participation in Fireside Chat Hosted by H.C. Wainwright & Co.

Jan 16, 2024, 8:00 AM EST - 2 years ago

Biora Therapeutics Provides Outlook for 2024

Jan 8, 2024, 8:00 AM EST - 2 years ago

Biora Therapeutics Announces Initiation of Phase 1 Clinical Study of BT-600

Jan 2, 2024, 8:00 AM EST - 2 years ago

Biora Therapeutics Progresses Research Collaboration for the BioJet™ Systemic Oral Delivery Platform

Dec 22, 2023, 7:00 AM EST - 2 years ago

Biora Therapeutics Registration statement: Registration Filing

Dec 19, 2023, 8:00 AM EST - 2 years ago

Biora Therapeutics Announces New Patent for its NaviCap™ Targeted Oral Delivery Platform

Dec 18, 2023, 8:00 AM EST - 2 years ago

Biora Therapeutics Accelerates Debt Reduction and Raises Capital with Large Institutional Investors

Dec 12, 2023, 4:38 PM EST - 2 years ago

Biora Therapeutics Slides: Corporate Presentation

Dec 11, 2023, 8:00 AM EST - 2 years ago

Biora Therapeutics Announces New Research Collaboration for the BioJet™ Systemic Oral Delivery Platform

Nov 30, 2023, 4:48 PM EST - 2 years ago

Biora Therapeutics Announces FDA Clearance of IND Application for Drug/Device Combination BT-600 Targeting Treatment of Ulcerative Colitis

Nov 13, 2023, 4:30 PM EST - 2 years ago

Biora Therapeutics Earnings Call Transcript: Q3 2023

Nov 13, 2023, 4:30 PM EST - 2 years ago

Biora Therapeutics Quarterly report: Q3 2023

Nov 13, 2023, 4:30 PM EST - 2 years ago

Biora Therapeutics Earnings release: Q3 2023

Nov 13, 2023, 4:05 PM EST - 2 years ago

Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Nov 6, 2023, 8:00 AM EST - 2 years ago

Biora Therapeutics to Report Third Quarter 2023 Financial Results and Provide Corporate Update

Oct 30, 2023, 4:05 PM EDT - 2 years ago

Biora Therapeutics Submits Updated IND Application for BT-600

Oct 23, 2023, 5:30 PM EDT - 2 years ago

Biora Therapeutics to Submit Updated IND Application for BT-600

Oct 5, 2023, 8:00 AM EDT - 2 years ago

Biora Therapeutics Presents Data on the BioJet™ Systemic Oral Delivery Platform at the 59th Annual Meeting of the European Association for the Study of Diabetes

Sep 25, 2023, 8:00 AM EDT - 2 years ago

Biora Therapeutics Announces Submission of IND Application to the U.S. FDA for BT-600 Program

Sep 19, 2023, 8:00 AM EDT - 2 years ago

Biora Therapeutics Reduces Debt and Largest Shareholder Increases Equity Exposure

Sep 11, 2023, 8:01 AM EDT - 2 years ago

Biora Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference

Sep 5, 2023, 8:00 AM EDT - 2 years ago

Biora Therapeutics Progresses its BioJet™ Systemic Oral Delivery Platform

Aug 14, 2023, 4:30 PM EDT - 3 years ago

Biora Therapeutics Earnings Call Transcript: Q2 2023

Aug 14, 2023, 4:30 PM EDT - 3 years ago

Biora Therapeutics Quarterly report: Q2 2023

Aug 14, 2023, 4:30 PM EDT - 3 years ago

Biora Therapeutics Earnings release: Q2 2023

Aug 14, 2023, 4:01 PM EDT - 3 years ago

Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results

Aug 3, 2023, 8:00 AM EDT - 3 years ago

Biora Therapeutics Announces New Patents Covering its BioJet™ Systemic Oral Delivery Platform

Aug 2, 2023, 8:00 AM EDT - 3 years ago

Biora Therapeutics to Participate in Canaccord Genuity 43rd Annual Growth Conference

Jul 27, 2023, 8:00 AM EDT - 3 years ago

Biora Therapeutics Announces Clinical Device Performance Study Results for its NaviCap™ Targeted Oral Delivery Platform

Jul 17, 2023, 6:00 AM EDT - 3 years ago

Biora Therapeutics to Report Second Quarter 2023 Financial Results and Provide Corporate Update

Jul 5, 2023, 8:00 AM EDT - 3 years ago

Biora Therapeutics Continues to Monetize Legacy Diagnostics Assets

Jun 28, 2023, 8:30 AM EDT - 3 years ago

Biora Therapeutics Announces New Patents for its NaviCap™ Targeted Oral Delivery Platform

Jun 26, 2023, 6:00 AM EDT - 3 years ago

Biora Therapeutics Presents Data on the BioJet™ Systemic Oral Delivery Platform at the American Diabetes Association 83rd Scientific Sessions

Jun 14, 2023, 4:05 PM EDT - 3 years ago

Biora Therapeutics Announces Closing of $8 Million Registered Direct Offering of Common Stock and Warrants Priced At-the-Market Under Nasdaq Rules

Coversoon Jun. 3 at 2:41 PM

$BIOR Criminals

0 · Reply

Herkules369 May. 30 at 3:24 PM

$BIOR Jackpo 🎰

0 · Reply

Coversoon May. 27 at 10:10 PM

$BIOR 25k watchers!!! On this pos. Sure!!! Criminal run enterprise led by a freaking liar. All should be have been prosecuted by doj including the board of directors

1 · Reply

Coversoon May. 27 at 10:06 PM

$BIOR C R I M I N A L S

0 · Reply

Rainbowz20 May. 25 at 8:04 PM

$BIOR does anyone know what happens to our shares when a company goes private. I had some shared in this POS for a long time I forgot about. Am UK based. Thanks

1 · Reply

Ajmh May. 20 at 11:28 AM

4 · Reply

Ajmh May. 20 at 11:25 AM

0 · Reply

jeni1988 May. 19 at 1:54 PM

$BIOR Alive?

0 · Reply

Ajmh May. 14 at 7:17 PM

$BIOR 🤦🏽🤦🏽🤦🏽🤦🏽🤦🏽🤦🏽🤦🏽🤦🏽🤦🏽 https://www.biospace.com/press-releases/biora-therapeutics-advances-biojet-swallowable-autoinjector

2 · Reply

Coversoon May. 8 at 4:07 PM

$BIOR C R I M I N A L S !!!!!!!

0 · Reply

Coversoon May. 6 at 12:48 PM

$BIOR people lost everything here!! Thanks to liars & criminals

1 · Reply

11thestate Apr. 30 at 2:37 PM

If you missed the deadline, don’t miss this update. You may still be able to recover losses from $BIOR — late claims are currently being accepted: https://11th.com/cases/progenity-investor-settlement This recovery fund was established after claims that Progenity misled investors about overbilling issues and financial risks ahead of its IPO. Even though the official deadline has passed, the court is still accepting late submissions. Who can apply? If you bought or held $BIOR between June 18, 2020, and December 2, 2020, you’re eligible — even if you already sold your shares

0 · Reply

Herkules369 Apr. 22 at 5:52 AM

$BIOR shares still exist, why?

1 · Reply

JCDollars Apr. 22 at 12:41 AM

$BIOR it’s like there leaving this company open , I wonder if something will take it over .

0 · Reply

j0hndee1 Apr. 18 at 5:46 PM

$BIOR waiting for the ceo to tell us the pill is a ai pill next why not lol

0 · Reply

JCDollars Mar. 3 at 12:18 AM

$BIOR where’s the green candles

0 · Reply

MonkFlip Jan. 26 at 9:47 PM

$BIOR Buy the dip!

0 · Reply

JCDollars Jan. 15 at 8:29 PM

$BIOR this shit alive

0 · Reply

Bolo44 Jan. 11 at 1:35 AM

$BIOR biggest scam in stock market history!!

0 · Reply

Timetoflytothemoon Jan. 5 at 1:19 PM

$ASBP asbp is on the rise! $IXHL $OLMA $OCGN $BIOR

0 · Reply

Coversoon Dec. 15 at 4:13 PM

$BIOR merry crookmas adi

0 · Reply

Coversoon Dec. 11 at 7:16 PM

$BIOR hey adi, who you going to scam next you big liar? Yea we know what you said in those earnings calls! If there was a regulatory agency in the US, you could have been held accountable. Anyway, you & your criminal buddies stole my money

0 · Reply

Market Cap	2.53M
Revenue (ttm)	4,000.00
Net Income (ttm)	-124.12M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	-0.18

Volume	498,178
Avg Vol	151,149
Day's Range	N/A - N/A
Shares Out	4.52M
Stochastic %K	16%
Beta	1.12
Analysts	Strong Sell
Price Target	$34.00